PGD2 Formation in Vascular Injury

University of Pennsylvania51 enrolled

Overview

To investigate the biosynthesis of PGD2 during percutaneous transluminal coronary angioplasty (PTCA) procedure.

A) To determine whether biosynthesis of PGD2 is altered in response to vascular injury in humans B) Patients will be grouped base on their aspirin using status. Three groups of no aspirin but an alternative anti-platelet medicine, low dose (81 mg) aspirin, high dose 325 mg aspirin will be enrolled.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Coronary Artery Disease Acute Coronary Syndrome Stable Angina

Interventions

No ASADRUG

Alternative antiplatelet therapy instead of aspirin

Low dose ASADRUG

Low dose aspirin (81mg) prior to PTCA

325 mg ASADRUG

high dose of aspirin prior to PTCA

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with existing CAD admitted for elective PTCA: 1. Treated with any dose of aspirin daily for at least 5 days, with special interest in those treated with 81 mg aspirin daily or 2. Treated with an alternative antiplatelet therapy, such as clopidogrel, due to aspirin hypersensitivity or PMDs preference or 3. No aspirin therapy at all * Patients presenting to the ER with Acute Coronary Syndrome(ACS)who will have a PTCA * Patients with stable angina or positive stress tests scheduled for a cardiac catheterization Exclusion Criteria: * History of unstable diabetes (hgb A1c\>8 or FBS\> 200) * Uncontrolled hypertension (SBP \> 180, DBP \>100) * History of an acute confounding disease as judged on clinical screen that according to the investigator may interfere with interpretation of the study results, or compromise the safety of a potential subject. * Patients who have taken NSAIDS or COX-2 inhibitors other than aspirin, for at least 10 days prior to PTCA

Outcomes

Primary Outcomes

The increment of PGD2 synthesis reflected by an novel biomarker of urinary PGD2 metabolite.

Time frame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.

Secondary Outcomes

Whether aspirin could blunt the increment of PGD2 if there is.

Time frame: 18-48 hours - which includes 24 hours before the procedure through 18 hours after the procedure for a continuous urine collection.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.